Clopidogrel and coronary stenting: What is the next question?

Journal of Thrombosis and Thrombolysis

Volumn 10, Issue 2, 2000, Pages 121-126

  Moore, S A ^a   Steinhubl, S R ^a  

^a WILFORD HALL MEDICAL CENTER   (United States)

Author keywords

Clopidogrel; Coronary stent

Indexed keywords

ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; TICLOPIDINE;

BLEEDING; BLOOD TOXICITY; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY ARTERY THROMBOSIS; CORONARY STENT; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERANCE; GASTROINTESTINAL SYMPTOM; HEART DEATH; HUMAN; LEUKOCYTE COUNT; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 0033760726     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018706324908     Document Type: Review

References (29)

1. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents
2. Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase
3. Structure and activity of the active metabolite of dopidogrel
4. Platelet anti-aggregating activity and tolerance of clopidogrel in atherosclerotic patients
5. Repeated-dose pharmacodynamics of clopidogrel in healthy subjects
6. Pharmacodynamics of ticlopidine in man in relation to plasma and blood cell concentration
7. Rapid onset of inhibition of ADP-induced platelet aggregation by a loading dose of clopidogrel
8. Intracoronary stenting and risk for major adverse cardiac events during the first month
9. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke
10. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high risk patients
11. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemia events
12. Antiplatelet drugs: A comparative review
13. Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases
14. Thrombotic thrombocytopenic purpura after stenting and ticlopidine
15. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators: Evaluation of Platelet IIb/IIIa Inhibitor for Stenting
16. Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention
17. Increasing mortality from thrombotic thrombocytopenic purpura in the United States-analysis of national mortality data
18. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation
19. Clopidogrel as adjunctive antiplatelet therapy during coronary stenting
20. Clopidogrel versus ticlopidine after intracoronary stent placement
21. Meeting highlights: Highlights of the 48th scientific sessions of the American College of Cardiology
22. Ticlid or plavix post-stent (TOPPS): Randomization to 2 weeks of treatment. Presented at Transcatheter Therapeutics (TCT), 1999
23. Cleveland Clinic Registry: 30-day outcomes after stenting
24. Washington Hospital Center Stent Registry: Ticlopidine and clopidogrel
25. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after placement of coronary-artery stents
26. A comparison of clopidogrel to ticlopidine therapy for the prevention of major adverse cardiac events at thirty days and six months following coronary stent implantation
27. Taming platelets in coronary stenting: Ticlopidine out, clopidogrel in?
28. Collaborative overview of randomised trials of antiplatelet therapy-II: Maintenance of vascular graft or arterial patency by antiplatelet therapy
29. Effects of clopidogrel, aspirin, and combined therapy in a porcine ex vivo model of high-shear induced stent thrombosis